Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SimVec-based COVID-19 vaccine
- Development stage
- Phase 1
- Lead developer
- GeneCure Biotechnologies
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
The SimVec-based COVID-19 vaccine is an investigational therapeutic COVID-19 vaccine developed by GeneCure Biotechnologies using the company's proprietary SimVec lentiviral delivery platform. It was designed for administration to infected patients or uninfected high-risk individuals with the goal of inducing rapid, strong cell-mediated immune responses that may help eliminate virally infected cells, prevent disease progression, and reduce viral transmission in COVID-19. The program entered first-in-human clinical testing in 2020 and represents a vaccine-focused application of the SimVec platform, which had previously been explored in HIV and hepatitis C therapeutic vaccine programs.
- Brand names
- Covax-19Covax19Covax 19
- Other names
- SimVec-based COVID-19 vaccineGeneCure SimVec-based COVID-19 vaccine
Beyond the preview
Go deeper on SimVec-based COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SimVec-based COVID-19 vaccine.